The pharmaceutical care of patients with hypertension: an examination of service models in primary care in the US

J.J. McAnaw, S.A. Hudson, A.M. McGregor

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: In the UK, the delivery of health care in cardiovascular disease is guided by 'national service frameworks', which are a source of standards of practice and evidence that help to define and aid the implementation of service models capable of responding to public health goals. The revised British Hypertension Society guidelines reflect a lower target blood pressure consistent with those recommended in the US and by the WHO. The lowering of the target for the control of blood pressure has increased the estimated proportion of treated patients with inadequate control in the UK from 37% to 72%. Objective: To identify the requirements for the provision of a pharmacy service that supports hypertension monitoring, and to gain insights into how such a service might be delivered as part of a wider provision of pharmaceutical care in the UK. Method: Two pharmacists followed a structured programme of observation involving three centres in the United States (Minnesota, Colorado and Iowa). Twelve clinical settings were observed, and the pharmacists who provided the services were also the subjects of documented interviews. The settings offered different models of pharmaceutical care from which issues relevant to the international development of such services were identified. Findings: Differences noted between the service models observed included; physical environment of the community pharmacy, the use and type of documentation, methods of blood pressure measurement, extent of monitoring and followup, interprofessional communication and service orientation in terms of the provision of comprehensive pharmaceutical care to patients or specific disease management. Conclusion: If clearly defined operational models of pharmaceutical care practice in the primary care setting are to form part of a national public health strategy in the UK, they must also be capable of responding to local opportunities and patients' needs. Future development of models and services must be patientcentred and more widely informed by the range of practice experience gained elsewhere.
LanguageEnglish
Pages189-194
Number of pages5
JournalPharmacy World and Science
Volume23
Issue number5
DOIs
Publication statusPublished - Oct 2001

Fingerprint

Pharmaceutical Services
Primary Health Care
Hypertension
Blood pressure
Pharmaceutical Preparations
Public health
Blood Pressure
Pharmacists
Public Health
Monitoring
Pharmacies
Disease Management
Pressure measurement
Health care
Documentation
Cardiovascular Diseases
Communication
Observation
Guidelines
Interviews

Keywords

  • blood pressure monitoring
  • cardiovascular disease
  • community pharmacy
  • documentation
  • hypertension
  • pharmaceutical care

Cite this

@article{6218c44bd18646ed9146634ce125f6c6,
title = "The pharmaceutical care of patients with hypertension: an examination of service models in primary care in the US",
abstract = "Background: In the UK, the delivery of health care in cardiovascular disease is guided by 'national service frameworks', which are a source of standards of practice and evidence that help to define and aid the implementation of service models capable of responding to public health goals. The revised British Hypertension Society guidelines reflect a lower target blood pressure consistent with those recommended in the US and by the WHO. The lowering of the target for the control of blood pressure has increased the estimated proportion of treated patients with inadequate control in the UK from 37{\%} to 72{\%}. Objective: To identify the requirements for the provision of a pharmacy service that supports hypertension monitoring, and to gain insights into how such a service might be delivered as part of a wider provision of pharmaceutical care in the UK. Method: Two pharmacists followed a structured programme of observation involving three centres in the United States (Minnesota, Colorado and Iowa). Twelve clinical settings were observed, and the pharmacists who provided the services were also the subjects of documented interviews. The settings offered different models of pharmaceutical care from which issues relevant to the international development of such services were identified. Findings: Differences noted between the service models observed included; physical environment of the community pharmacy, the use and type of documentation, methods of blood pressure measurement, extent of monitoring and followup, interprofessional communication and service orientation in terms of the provision of comprehensive pharmaceutical care to patients or specific disease management. Conclusion: If clearly defined operational models of pharmaceutical care practice in the primary care setting are to form part of a national public health strategy in the UK, they must also be capable of responding to local opportunities and patients' needs. Future development of models and services must be patientcentred and more widely informed by the range of practice experience gained elsewhere.",
keywords = "blood pressure monitoring, cardiovascular disease, community pharmacy, documentation, hypertension, pharmaceutical care",
author = "J.J. McAnaw and S.A. Hudson and A.M. McGregor",
year = "2001",
month = "10",
doi = "10.1023/A:1012227018705",
language = "English",
volume = "23",
pages = "189--194",
journal = "Pharmacy World and Science",
issn = "0928-1231",
number = "5",

}

The pharmaceutical care of patients with hypertension : an examination of service models in primary care in the US. / McAnaw, J.J.; Hudson, S.A.; McGregor, A.M.

In: Pharmacy World and Science, Vol. 23, No. 5, 10.2001, p. 189-194.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The pharmaceutical care of patients with hypertension

T2 - Pharmacy World and Science

AU - McAnaw, J.J.

AU - Hudson, S.A.

AU - McGregor, A.M.

PY - 2001/10

Y1 - 2001/10

N2 - Background: In the UK, the delivery of health care in cardiovascular disease is guided by 'national service frameworks', which are a source of standards of practice and evidence that help to define and aid the implementation of service models capable of responding to public health goals. The revised British Hypertension Society guidelines reflect a lower target blood pressure consistent with those recommended in the US and by the WHO. The lowering of the target for the control of blood pressure has increased the estimated proportion of treated patients with inadequate control in the UK from 37% to 72%. Objective: To identify the requirements for the provision of a pharmacy service that supports hypertension monitoring, and to gain insights into how such a service might be delivered as part of a wider provision of pharmaceutical care in the UK. Method: Two pharmacists followed a structured programme of observation involving three centres in the United States (Minnesota, Colorado and Iowa). Twelve clinical settings were observed, and the pharmacists who provided the services were also the subjects of documented interviews. The settings offered different models of pharmaceutical care from which issues relevant to the international development of such services were identified. Findings: Differences noted between the service models observed included; physical environment of the community pharmacy, the use and type of documentation, methods of blood pressure measurement, extent of monitoring and followup, interprofessional communication and service orientation in terms of the provision of comprehensive pharmaceutical care to patients or specific disease management. Conclusion: If clearly defined operational models of pharmaceutical care practice in the primary care setting are to form part of a national public health strategy in the UK, they must also be capable of responding to local opportunities and patients' needs. Future development of models and services must be patientcentred and more widely informed by the range of practice experience gained elsewhere.

AB - Background: In the UK, the delivery of health care in cardiovascular disease is guided by 'national service frameworks', which are a source of standards of practice and evidence that help to define and aid the implementation of service models capable of responding to public health goals. The revised British Hypertension Society guidelines reflect a lower target blood pressure consistent with those recommended in the US and by the WHO. The lowering of the target for the control of blood pressure has increased the estimated proportion of treated patients with inadequate control in the UK from 37% to 72%. Objective: To identify the requirements for the provision of a pharmacy service that supports hypertension monitoring, and to gain insights into how such a service might be delivered as part of a wider provision of pharmaceutical care in the UK. Method: Two pharmacists followed a structured programme of observation involving three centres in the United States (Minnesota, Colorado and Iowa). Twelve clinical settings were observed, and the pharmacists who provided the services were also the subjects of documented interviews. The settings offered different models of pharmaceutical care from which issues relevant to the international development of such services were identified. Findings: Differences noted between the service models observed included; physical environment of the community pharmacy, the use and type of documentation, methods of blood pressure measurement, extent of monitoring and followup, interprofessional communication and service orientation in terms of the provision of comprehensive pharmaceutical care to patients or specific disease management. Conclusion: If clearly defined operational models of pharmaceutical care practice in the primary care setting are to form part of a national public health strategy in the UK, they must also be capable of responding to local opportunities and patients' needs. Future development of models and services must be patientcentred and more widely informed by the range of practice experience gained elsewhere.

KW - blood pressure monitoring

KW - cardiovascular disease

KW - community pharmacy

KW - documentation

KW - hypertension

KW - pharmaceutical care

U2 - 10.1023/A:1012227018705

DO - 10.1023/A:1012227018705

M3 - Article

VL - 23

SP - 189

EP - 194

JO - Pharmacy World and Science

JF - Pharmacy World and Science

SN - 0928-1231

IS - 5

ER -